CyGen Alpha Systems is proud to recognize two members of its Advisory Board who were honored at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, one of the world’s leading conferences for nuclear medicine, molecular imaging, and radiopharmaceutical science.
Dr. Peter J. H. Scott Receives the 2026 Michael J. Welch, PhD Award
CyGen Advisor Dr. Peter J. H. Scott was awarded the prestigious 2026 Michael J. Welch, PhD Award, which recognizes individuals who have made outstanding contributions to radiopharmaceutical sciences, mentorship, and advancement of the nuclear medicine community.
Dr. Scott serves as Chief of Nuclear Medicine and Director of the PET Center at the University of Michigan and is internationally recognized for his work in radiochemistry, PET imaging, and isotope production technologies.
(Read more about the Michael J. Welch PhD Award by clicking here)
Dr. Tadashi Watabe Earns JNM Editors’ Choice Honors
CyGen Advisor Dr. Tadashi Watabe received both the Best Clinical Article Award and the Overall Best Article Award from the Journal of Nuclear Medicine for his groundbreaking publication:
The study represents one of the first human clinical investigations of Astatine-211 (At-211) targeted alpha therapy and highlights the growing momentum behind next-generation alpha-emitting radiopharmaceuticals.
Advancing the Future of Radiopharmaceutical Infrastructure
The recognition of both Dr. Scott and Dr. Watabe underscores the caliber of scientific and clinical expertise supporting CyGen’s mission to expand domestic radiopharmaceutical production infrastructure.
As targeted alpha therapies continue to advance from research into clinical practice, CyGen remains focused on helping address the critical isotope supply bottleneck through the development of advanced GMP-compliant production facilities designed to support the next generation of cancer imaging and treatment.
CyGen congratulates Dr. Scott and Dr. Watabe on these significant achievements and their continued contributions to the advancement of nuclear medicine and precision oncology.